Evolent Health, Inc. (EVH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.05%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 2.05% | Share-based compensation / revenue. Period ending 2026-06-30. $42.93M ÷ $2.10B × 100 ≈ 2.05% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 2.10B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 42.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -427.50M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.10B | $42.93M | $-427.50M | (m) | (m) | 2.05% | (m) | (m) |
| 2026-03-31 | (m) | $1.89B | $39.31M | $-419.12M | (m) | (m) | 2.08% | (m) | (m) |
| 2025-12-31 | (m) | $1.88B | $39.74M | $-410.14M | (m) | (m) | 2.12% | (m) | (m) |
| 2025-09-30 | (m) | $2.05B | $31.23M | $-20.50M | (m) | (m) | 1.52% | (m) | (m) |
| 2025-06-30 | (m) | $2.20B | $30.96M | $-37.66M | (m) | (m) | 1.41% | (m) | (m) |
| 2025-03-31 | (m) | $2.40B | $32.04M | $-28.70M | (m) | (m) | 1.34% | (m) | (m) |
| 2024-12-31 | (m) | $2.55B | $39.75M | $-40.48M | (m) | (m) | 1.56% | (m) | (m) |
| 2024-09-30 | (m) | $2.46B | $56.46M | $-43.24M | (m) | (m) | 2.29% | (m) | (m) |
| 2024-06-30 | (m) | $2.35B | $52.27M | $-44.91M | (m) | (m) | 2.22% | (m) | (m) |
| 2024-03-31 | (m) | $2.18B | $48.58M | $-74.27M | $47.31M | (m) | 2.23% | -1.57× | Reported |
| 2023-12-31 | (m) | $1.96B | $40.50M | $-71.21M | $54.20M | (m) | 2.06% | -1.31× | Reported |
| 2023-09-30 | (m) | $1.79B | $44.53M | $-51.74M | $48.40M | (m) | 2.49% | -1.07× | Reported |
| 2023-06-30 | (m) | $1.63B | $41.30M | $-20.85M | $38.54M | (m) | 2.53% | -0.54× | Reported |
| 2023-03-31 | (m) | $1.48B | $39.34M | $-3.92M | $26.23M | (m) | 2.65% | -0.15× | Reported |
| 2022-12-31 | (m) | $1.35B | $33.98M | $3.64M | $15.57M | (m) | 2.51% | 0.23× | Reported |
| 2022-09-30 | $16.10M | $1.22B | $24.31M | $-6.69M | $15.59M | 1.32% | 2.00% | -0.43× | Reported |
| 2022-06-30 | (m) | $1.09B | $21.71M | $-26.23M | $17.20M | (m) | 2.00% | -1.52× | Reported |
| 2022-03-31 | $16.20M | $989.94M | $18.35M | $-29.26M | $21.33M | 1.64% | 1.85% | -1.37× | Reported |
| 2021-12-31 | $15.50M | $907.96M | $16.71M | $-42.41M | $25.43M | 1.71% | 1.84% | -1.67× | Reported |
| 2021-09-30 | (m) | $931.52M | $15.98M | $-33.45M | $27.33M | (m) | 1.72% | -1.22× | Reported |
| 2021-06-30 | (m) | $973.64M | $14.75M | $-43.32M | $28.38M | (m) | 1.52% | -1.53× | Reported |
| 2021-03-31 | (m) | $990.22M | $14.80M | $-261.48M | $28.39M | (m) | 1.50% | -9.21× | Reported |
| 2020-12-31 | $15.10M | $1.02B | $14.61M | $-270.62M | $28.34M | 1.48% | 1.43% | -9.55× | Reported |
| 2020-09-30 | (m) | $987.03M | $10.95M | $-485.27M | $23.72M | (m) | 1.11% | -20.46× | Reported |
| 2020-06-30 | (m) | $942.59M | $13.54M | $-487.70M | $19.93M | (m) | 1.44% | -24.47× | Reported |
| 2020-03-31 | (m) | $895.91M | $14.59M | $-285.47M | $17.26M | (m) | 1.63% | -16.54× | Reported |
| 2019-12-31 | $19.80M | $846.38M | $15.62M | $-306.61M | $14.53M | 2.34% | 1.85% | -21.10× | Reported |
| 2019-09-30 | (m) | $802.96M | $20.09M | $-105.37M | $13.73M | (m) | 2.50% | -7.67× | Reported |
| 2019-06-30 | (m) | $732.77M | $18.38M | $-96.26M | $10.96M | (m) | 2.51% | -8.78× | Reported |
| 2019-03-31 | (m) | $685.11M | $18.35M | $-79.99M | $8.19M | (m) | 2.68% | -9.76× | Reported |
| 2018-12-31 | $18.20M | $627.06M | $17.61M | $-47.48M | $5.48M | 2.90% | 2.81% | -8.66× | Reported |
| 2018-09-30 | (m) | (m) | $16.82M | $-52.38M | $3.42M | (m) | (m) | -15.33× | Reported |
| 2018-06-30 | (m) | (m) | $18.49M | $-55.37M | $3.44M | (m) | (m) | -16.08× | Reported |
| 2018-03-31 | (m) | (m) | $19.13M | $-65.52M | $3.54M | (m) | (m) | -18.53× | Reported |
| 2017-12-31 | $17.20M | (m) | $20.44M | $-72.84M | $3.64M | (m) | (m) | -20.03× | Reported |
| 2017-09-30 | (m) | (m) | $20.93M | $-88.47M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $20.02M | $-90.28M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $19.37M | $-83.80M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $11.10M | (m) | $18.60M | $-237.42M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $18.04M | $-217.73M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $18.09M | $-219.61M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $19.17M | $-218.15M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $5.80M | (m) | $14.73M | $-42.97M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $0.00 | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $2.00M | (m) | $91.00K | $-21.16M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FRANKLIN COVEY CO (FC) | United States | $0.195B | 123.76 |
| GARTNER INC (IT) | United States | $11.326B | 11.20 |